NCT03826862 is a NA clinical trial of CT three-dimensional reconstruction in Rectal Cancer, sponsored by Ziqiang Wang,MD.

Who is sponsoring NCT03826862?

NCT03826862 is sponsored by Ziqiang Wang,MD.

What drugs are being tested in NCT03826862?

Interventions in NCT03826862: CT three-dimensional reconstruction.

What condition does NCT03826862 study?

NCT03826862 studies Rectal Cancer.

Is NCT03826862 still recruiting?

NCT03826862 is currently status unknown. Last updated 1 February 2019.

Last reviewed 2019-02-01 · How we verify

NCT03826862

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lateral Lymph Node Dissection for Middle-low Rectal Cancer

Status unknown NA Last updated 1 February 2019

What this trial tests

NA trial testing CT three-dimensional reconstruction in Rectal Cancer in 30 participants. Status unknown.

Timeline

1 October 2018

Primary endpoint
31 December 2020

30 December 2022

Quick facts

Lead sponsor	Ziqiang Wang,MD
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 October 2018
Primary completion	31 December 2020
Estimated completion	30 December 2022
Sites	1 location across China

Drugs / interventions tested

CT three-dimensional reconstruction

Conditions studied

Rectal Cancer — all drugs for Rectal Cancer →

Sponsor

Ziqiang Wang,MD

Who can join

Adults 18 to 80, any sex, with Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will perform CT three-dimension reconstruction for middle-low rectal cancer patients who have enlarged lateral lymph nodes to recognize the variance of pelvic vessels, by which to help reduce operative time and blood loss, localize the lateral lymph nodes, improve the lymph node harvested and positive rate. Besides, The investigators will label the vessels near the interested node to achieve node-by-node for further investigation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Can patients with good tumor regression grading after neoadjuvant chemoradiotherapy be exempted from lateral lymph node dissection?
Liu X, Yang X, Wu Q, Zhang T, et al · · 2022 · cited 2× · PMID 36581784 · DOI 10.1007/s12672-022-00607-w
Discrepancies in the Reactivity of Mesorectal versus Lateral Lymph Nodes Post-Neoadjuvant Chemoradiotherapy for Rectal Cancer: Insights from Radiological and Pathological Perspectives.
Zhuang Z, Yang X, Zhang Y, Deng X, et al · · 2025 · PMID 40640480 · DOI 10.1245/s10434-025-17777-w

Verify or expand the search:

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
NCT07501845 — Registry Maastro Applicator · recruiting
NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting

Other Ziqiang Wang,MD trials

Trials by the same sponsor.

NCT04392609 — Predicting Locally Advanced Rectal Cancer Response to NCT and NCRT With MRI · unknown
NCT03930082 — Frailty Assessment of Patients With Gastrointestinal Surgery · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03826862 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ziqiang Wang,MD
Last refreshed: 1 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03826862.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing